Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Charles V. Pollack^*, Paul A. Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V. Huisman, Elaine Hylek, Chak Wah Kam, Pieter W. Kamphuisen, Joerg Kreuzer, Jerrold H. Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Jeffrey I. Weitz